Breaking News: BioAge Labs Secures $170M in Funding for Groundbreaking Aging-Biology Therapies

BioAge Labs is excited to announce that it has successfully raised $170 million in its latest funding round, marking a significant milestone in the company’s mission to revolutionize the treatment of metabolic diseases through the biology of human aging. As a clinical-stage biotechnology firm, BioAge is at the forefront of innovation, leveraging its proprietary platform that incorporates over 65 million molecular measurements acquired across 45 years of clinical data. This extensive database not only uncovers novel biological insights but also identifies potential druggable mechanisms for age-related diseases. Central to this funding endeavor is the advancement of BioAge's leading candidate, azelaprag, an orally administered APJ agonist now entering Phase 2 trials in combination with tirzepatide for treating obesity in older adults. With the potential to enhance weight loss and improve body composition in patients undergoing incretin therapy, azelaprag represents a groundbreaking step toward effective obesity management tailored for aging populations. Further, this funding will bolster our preclinical programs that explore critical pathways in metabolic aging based on our unique discovery platform. BioAge is not only committed to scientific excellence but also prides itself on fostering an inclusive workplace, offering a comprehensive benefits package that supports employee well-being and career development. Our dedication to diversity and equal opportunity underscores the belief that every individual contributes uniquely to our collective success, as we strive to push the boundaries of biomedical research and improve health outcomes for aging populations.